Literature DB >> 11950779

Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization.

Thomayant Prueksaritanont1, Raju Subramanian, Xiaojun Fang, Bennett Ma, Yue Qiu, Jiunn H Lin, Paul G Pearson, Thomas A Baillie.   

Abstract

The active forms of all marketed hydroxymethylglutaryl (HMG)-CoA reductase inhibitors share a common dihydroxy heptanoic or heptenoic acid side chain. In this study, we present evidence for the formation of acyl glucuronide conjugates of the hydroxy acid forms of simvastatin (SVA), atorvastatin (AVA), and cerivastatin (CVA) in rat, dog, and human liver preparations in vitro and for the excretion of the acyl glucuronide of SVA in dog bile and urine. Upon incubation of each statin (SVA, CVA or AVA) with liver microsomal preparations supplemented with UDP-glucuronic acid, two major products were detected. Based on analysis by high-pressure liquid chromatography, UV spectroscopy, and/or liquid chromatography (LC)-mass spectrometry analysis, these metabolites were identified as a glucuronide conjugate of the hydroxy acid form of the statin and the corresponding delta-lactone. By means of an LC-NMR technique, the glucuronide structure was established to be a 1-O-acyl-beta-D-glucuronide conjugate of the statin acid. The formation of statin glucuronide and statin lactone in human liver microsomes exhibited modest intersubject variability (3- to 6-fold; n = 10). Studies with expressed UDP glucuronosyltransferases (UGTs) revealed that both UGT1A1 and UGT1A3 were capable of forming the glucuronide conjugates and the corresponding lactones for all three statins. Kinetic studies of statin glucuronidation and lactonization in liver microsomes revealed marked species differences in intrinsic clearance (CL(int)) values for SVA (but not for AVA or CVA), with the highest CL(int) observed in dogs, followed by rats and humans. Of the statins studied, SVA underwent glucuronidation and lactonization in human liver microsomes, with the lowest CL(int) (0.4 microl/min/mg of protein for SVA versus approximately 3 microl/min/mg of protein for AVA and CVA). Consistent with the present in vitro findings, substantial levels of the glucuronide conjugate (approximately 20% of dose) and the lactone form of SVA [simvastatin (SV); approximately 10% of dose] were detected in bile following i.v. administration of [(14)C]SVA to dogs. The acyl glucuronide conjugate of SVA, upon isolation from an in vitro incubation, underwent spontaneous cyclization to SV. Since the rate of this lactonization was high under conditions of physiological pH, the present results suggest that the statin lactones detected previously in bile and/or plasma following administration of SVA to animals or of AVA or CVA to animals and humans, might originate, at least in part, from the corresponding acyl glucuronide conjugates. Thus, acyl glucuronide formation, which seems to be a common metabolic pathway for the hydroxy acid forms of statins, may play an important, albeit previously unrecognized, role in the conversion of active HMG-CoA reductase inhibitors to their latent delta-lactone forms.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11950779     DOI: 10.1124/dmd.30.5.505

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  63 in total

1.  Effect of statins on estrogen and androgen levels in postmenopausal women treated with estradiol.

Authors:  A Peck; S Chaikittisilpa; R Mirzaei; J Wang; W J Mack; H N Hodis; F Z Stanczyk
Journal:  Climacteric       Date:  2010-05-07       Impact factor: 3.005

Review 2.  Toxicity of antilipidemic agents: facts and fictions.

Authors:  Antonios M Xydakis; Peter H Jones
Journal:  Curr Atheroscler Rep       Date:  2003-09       Impact factor: 5.113

3.  Diabetes mellitus reduces the clearance of atorvastatin lactone: results of a population pharmacokinetic analysis in renal transplant recipients and in vitro studies using human liver microsomes.

Authors:  Miroslav Dostalek; Wai-Johnn Sam; Komal R Paryani; Joyce S Macwan; Reginald Y Gohh; Fatemeh Akhlaghi
Journal:  Clin Pharmacokinet       Date:  2012-09-01       Impact factor: 6.447

4.  Population pharmacokinetic analysis of simvastatin and its active metabolite with the characterization of atypical complex absorption kinetics.

Authors:  Seok-Joon Jin; Kyun-Seop Bae; Sang-Heon Cho; Jin-Ah Jung; Unjib Kim; Sangmin Choe; Jong-Lyul Ghim; Yook-Hwan Noh; Hyun-Jung Park; Hee-Sun Kim; Hyeong-Seok Lim
Journal:  Pharm Res       Date:  2014-02-19       Impact factor: 4.200

5.  Efficacy and cytotoxicity in cell culture of novel α-hydroxytropolone inhibitors of hepatitis B virus ribonuclease H.

Authors:  Elena Lomonosova; Jil Daw; Aswin K Garimallaprabhakaran; Nana B Agyemang; Yashkumar Ashani; Ryan P Murelli; John E Tavis
Journal:  Antiviral Res       Date:  2017-06-17       Impact factor: 5.970

6.  Atorvastatin metabolite measurements as a diagnostic tool for statin-induced myopathy.

Authors:  Ine B Skottheim; Martin P Bogsrud; Monica Hermann; Kjetil Retterstøl; Anders Åsberg
Journal:  Mol Diagn Ther       Date:  2011-08-01       Impact factor: 4.074

Review 7.  Pediatric pharmacogenomics: a systematic assessment of ontogeny and genetic variation to guide the design of statin studies in children.

Authors:  Jonathan Wagner; J Steven Leeder
Journal:  Pediatr Clin North Am       Date:  2012-08-22       Impact factor: 3.278

8.  Genetic variation in the UGT1A locus is associated with simvastatin efficacy in a clinical practice setting.

Authors:  Otito F Iwuchukwu; QiPing Feng; Wei-Qi Wei; Lan Jiang; Min Jiang; Hua Xu; Joshua C Denny; Russell A Wilke; Ronald M Krauss; Dan M Roden; C Michael Stein
Journal:  Pharmacogenomics       Date:  2014-11       Impact factor: 2.533

9.  Atorvastatin attenuation of ABCB1 expression is mediated by microRNA miR-491-3p in Caco-2 cells.

Authors:  Alice C Rodrigues; Elida Adalgisa Neri; Sidney Veríssimo-Filho; Nancy Amaral Rebouças; Rosario D C Hirata; Ai-Ming Yu
Journal:  Eur J Pharm Sci       Date:  2016-08-26       Impact factor: 4.384

10.  UGT1A1*28 is associated with decreased systemic exposure of atorvastatin lactone.

Authors:  Camilla Stormo; Martin P Bogsrud; Monica Hermann; Anders Åsberg; Armin P Piehler; Kjetil Retterstøl; Marianne K Kringen
Journal:  Mol Diagn Ther       Date:  2013-08       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.